1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Medios AG

Medios AG

MEDOF
Medios AGUS flagOther OTC
50.00
USD
- -
- -
1.28BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
127.12
30.62
19.86
23.8
35.49
40.55
67.75
67.79
74.97
76.01
82.99
86.55
Basic EPS, GAAP
-0.39
-0.07
1.61
-0.73
0.32
0.31
0.67
0.36
0.37
0.77
0.79
0.51
0.61
0.57
Free Cash Flow per Basic Share
0.24
0.03
2.58
-0.45
-0.35
-0.36
-0.17
-2.78
2.43
1.35
0.64
2.72
1.76
2.1
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.16
1.83
2.3
1.2
1.49
2.08
2.42
2.58
2.98
3.77
4.19
4.76
5.07
Tangible Book Value per Share
0.02
1.22
2.87
6.15
2.85
2.82
3.46
6.94
10.05
6.88
7.6
0.01
1.18
1.68
Basic Weighted Avg Shares
- -
- -
- -
4
13
14
15
15
20
24
24
25
25
25
Sales/Revenue/Turnover
- -
- -
58
133
254
328
517
627
1,357
1,611
1,785
1,883
2,079
2,122
Operating Margin (%)
-60,286.72
-2,250
1.83
-0.67
2.62
2.16
2.54
1.46
1.01
1.67
1.71
1.62
2.04
1.96
Depreciation Expense
- -
- -
- -
- -
- -
1
2
4
19
22
21
31
38
38
Net Income, GAAP
- -
- -
1
-3
4
4
10
6
7
18
19
13
15
14
Effective Tax Rate (%)
- -
- -
30.52
- -
38.4
41.36
31.37
37.93
45.48
34.12
35.96
42.58
44.92
48.06
Profit Margin (%)
-50,645.54
-825
1.27
-2.38
1.63
1.32
1.89
0.88
0.55
1.14
1.05
0.67
0.74
0.66
Working Capital
- -
1
1
26
31
37
51
106
207
168
186
175
162
176
LT Debt
- -
- -
- -
- -
- -
- -
3
17
15
15
15
206
159
- -
Total Equity
- -
1
1
34
46
70
82
142
394
448
469
510
514
520
Return on Invested Capital (%)
- -
- -
62.78
- -
9.92
6.93
10.7
4.38
2.36
3.72
3.97
2.73
3.08
3.94
Return on Capital (%)
- -
- -
161.72
- -
30.68
24.04
34.48
12.75
10.57
20.19
20.84
8.38
7.97
19.81
Return on Common Equity (%)
-182.73
-79.7
161.72
-58.57
32.61
24.06
38.31
16.31
16.63
29.94
23.44
12.96
13.77
11.89

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
30
- -
LT Borrowings
- -
130
- -
LT Finance Leases
- -
29
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
25
25
Market Capitalization
1,087
1,086
1,061

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
374
344
366
Cash, Cash Equivalents & STI
93
82
94
Accounts Receivable, Net
168
143
168
Inventories
92
90
87
Total Current Liabilities
215
181
190
Payables & Accruals
- -
- -
- -
ST Debt
- -
30
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
286.23%
40.93%
0.79%
Free Cash Flow
143.02%
1.97%
-34.7%
Net Income, GAAP
-49.91%
34.67%
22.45%
Sales/Revenue/Turnover
48.94%
32.4%
10.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
456
451
493
483
1,883
2025
485
507
538
549
2,079
2026
528
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
- -
- -
- -
0.51
2025
0.25
- -
- -
- -
0.61
2026
0.2
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Thomas Meier
Full Time Employees
993
Sector
Healthcare
Industry
Medical - Distribution
Address
Heidestrasse 9 Berlin BC Germany 10557
IPO Date
Nov 10, 2021
Website
medios.ag
Similar Companies
Sopharma AD (SPH.WA)
Arjo AB (publ) (ARJO-B.ST)
Henry Schein, Inc. (HS2.DE)
Wanjia Group Holdings Limited (0401.HK)
Medios AG (0QB4.L)
Rajnish Wellness Limited (RAJNISH.BO)
Business
Medios AG, a leading provider of specialty pharmaceutical solutions in Europe, specializes in the supply of high-priced medications for rare and chronic diseases and the compounding of patient-specific therapies. The company operates through Pharmaceutical Supply and Patient-Specific Therapies segments, offering finished specialty pharma products in oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia; patient-specific preparations including cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products; and services such as patient health protection, optimized medication management through blistering, digitalization of data, and support for clinical trials under Good Manufacturing Practice standards. Founded in 2015 and headquartered in Berlin, Germany, Medios maintains a regional supply network with nine locations across Germany, including seven manufacturing sites and four pharmaceutical supply centers, and extends operations to the Netherlands, Belgium, and Spain through recent expansion. Targeting pharmacies, medical specialists, hospitals, and pharmaceutical companies, Medios focuses on individualized medicine for complex conditions like cancer, multiple sclerosis, and autoimmune diseases, ensuring reliable access via temperature-controlled logistics from -80°C to +25°C. In March 2024, Medios acquired Ceban Pharmaceuticals B.V., the Dutch market leader in pharmaceutical compounding, for a cash component of €235.3 million plus 1.7 million new shares valued at €23.9 million, internationalizing its business model and adding expected 2023 revenue of €160 million and EBITDA of €29 million; the deal closed in Q2 2024 with financing from existing cash and a €200 million credit facility. Recent developments include strong financial performance with 9.2% revenue growth to achieve significant increases in the first nine months of 2025, organic EBITDA pre growth of 5.1%, nearly doubled cash flow from operating activities, and confirmation of full-year outlook; additionally, Thomas Meier was appointed as new CEO effective February 1, 2026, and the company completed a public share buyback offer for up to 1 million shares in 2025.

Company News

APIChatGPT

  • seekingalpha.com

    Medios AG (MEDOF) Q3 2025 Earnings Call Prepared Remarks Transcript